• Ganesh Kumar Veeramachaneni
  • Kranthi Raj K
  • Bondili Js
  • Venkateswara Rao Talluri


Objective: Obesity was considered as a serious health concern apart from the age group in today's population globally. The percentage of obese people
in the world's population is increasing at a faster rate, and health issues arising due to obesity are gradually increasing. Our present insilico study was
aimed to screen out natural molecules against the peroxisome proliferator-activated receptor (PPAR), especially alpha aids in triggering the obesity.
Methods: Several targets for treating obesity were identified, and one among such promising target was PPAR. Using the insilico applications such as
natural database was screened and the molecules were further evaluated based on their docking score parameter with the receptor.
Results: The docking methodology suggested that two molecules zinc02091671 and zinc02137525 were found to reproduce the similar type of
interactions such as that of the known inhibitor and crystal ligand.
Conclusion: The reported two molecules were found to be promising agonists based on the computational studies and can be advanced the in vitro
based evaluation.
Keywords: Obesity, Peroxisome proliferator-activated receptor, e-pharmacophore, QikProp, Docking.


Download data is not yet available.



Siraj FM, SathishKumar N, Kim YJ, Kim SY, Yang DC. Ginsenoside F2

possesses anti-obesity activity via binding with PPAR? and inhibiting

adipocyte differentiation in the 3T3-L1 cell line. J Enzyme Inhib Med

Chem 2015;30(1):9-14.

Veeramachaneni GK, Raj KK, Chalasani LM, Bondili JS, Talluri VR.


High-throughput virtual screening with e-pharmacophore and molecular

simulations study in the designing of pancreatic lipase inhibitors. Drug

Des Devel Ther 2015;9:4397-412.

Barish GD, Narkar VA, Evans RM. PPAR delta: A dagger in the heart

of the metabolic syndrome. J Clin Invest 2006;116(3):590-7.

Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for

metabolic disease. Trends Pharmacol Sci 2005;26(5):244-51.

Evans RM, Barish GD, Wang YX. PPARs and the complex journey to

obesity. Nat Med 2004;10(4):355-61.

Fruchart JC. Peroxisome proliferator - Activated receptor-alpha

(PPARα): At the crossroads of obesity, diabetes and cardiovascular

disease. Atherosclerosis 2009;205(1):1-8.

Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, et al.

Improvement of dyslipidemia, insulin sensitivity, and energy balance by

a peroxisome proliferator-activated receptor alpha agonist. Metabolism


Zhang F, Lavan B, Gregoire FM. Peroxisome proliferator-activated

receptors as attractive antiobesity targets. Drug News Perspect


Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE, et al.

Hypertrophy and/or hyperplasia: Dynamics of adipose tissue growth.

PLoS Comput Biol 2009;5(3):e1000324.

Bourgeois F, Alexiu A, Lemonnier D. Dietary-induced obesity:

Effect of dietary fats on adipose tissue cellularity in mice. Br J Nutr


Costet P, Legendre C, Moré J, Edgar A, Galtier P, Pineau T. Peroxisome

proliferator-activated receptor alpha-isoform deficiency leads to

progressive dyslipidemia with sexually dimorphic obesity and steatosis.

J Biol Chem 1998;273(45):29577-85.

Ma Y, Wang SQ, Xu WR, Wang RL, Chou KC. Design novel

dual agonists for treating type-2 diabetes by targeting peroxisome

proliferator-activated receptors with core hopping approach. PLoS One


Loving K, Salam NK, Sherman W. Energetic analysis of fragment

docking and application to structure-based pharmacophore hypothesis

generation. J Comput Aided Mol Des 2009;23(8):541-54.

Salam NK, Nuti R, Sherman W. Novel method for generating structurebased

pharmacophores using energetic

analysis. J


Inf Model


Dixon SL, Smondyrev AM, Rao SN. PHASE: A novel approach to

pharmacophore modeling and 3D database searching. Chem Biol Drug

Des 2006;67(5):370-2.

Samal SK, Routray S, Veeramachaneni GK, Dash R, Botlagunta M.

Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral

cancer. Sci Rep 2015;5:9982.

Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL,

et al. Structural determinants of ligand binding selectivity between the

peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A


Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W.

Protein and ligand preparation: Parameters, protocols, and influence

on virtual screening enrichments. J Comput Aided Mol Des


Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing

of the OPLS all-atom force field on conformational energetics and

properties of organic liquids. J Am Chem Soc 1996;118:11225-36.

Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W.

Prediction of absolute solvation free energies using molecular dynamics

free energy perturbation and the OPLS force field. J Chem Theory

Comput 2010;6(5):1509-19.

Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT,

et al. Glide: A new approach for rapid, accurate docking and

scoring 1. Method and assessment of docking accuracy. J Med Chem


Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR,

Halgren TA, et al. Extra precision glide: Docking and scoring

incorporating a model of hydrophobic enclosure for protein-ligand

complexes. J Med Chem 2006;49(21):6177-96.

Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL,

Pollard WT, et al. Glide: A new approach for rapid, accurate docking

and scoring 2. Enrichment factors in database screening. J Med Chem




How to Cite

Veeramachaneni, G. K., K. Raj K, B. Js, and V. R. Talluri. “SCREENING AND MOLECULAR DOCKING STUDIES OF NEW NATURAL AGONISTS AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA TARGETED TO TREAT OBESITY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 4, July 2016, pp. 80-84,



Original Article(s)